logo
Share SHARE
FONT-SIZE Plus   Neg

European Commission Oks Novartis' Afinitor Tablets For Treatment Of HR+/HER2

Novartis International AG (NVS: Quote) said the European Commission has approved Afinitor (everolimus) tablets for treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

The approval was based on the Phase III BOLERO-2 trial. The randomized, double-blind, placebo-controlled, multi-center study of 724 patients found that treatment with Afinitor plus exemestane more than doubled median progression-free survival, or PFS, to 7.8 months, compared to 3.2 months with exemestane alone, by local investigator assessment.

Besides, an additional analysis based on an independent central radiology review showed Afinitor extended median PFS to 11.0 months compared to 4.1 months. The most common grade 3-4 adverse reactions were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis and diarrhea.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Warner Bros. Interactive Entertainment said its upcoming mobile game releases in 2015 would include Batman, DC Comics, LEGO, "Game of Thrones," and "Mortal Combat X". A study claims the ghastly civil war in Syria is the result of a severe drought brought about by global warming - in what is yet the strongest link between climate change and armed conflict. U.S. electronics giant Apple Inc. (AAPL) regained the top spot in the world smartphone market from South Korea's Samsung Electronics Co Ltd. after a gap of three years, according to a report released Tuesday by market research firm Gartner, Inc. (IT). Apple sold 74.832 million smartphones in the...
comments powered by Disqus
RELATED NEWS
Trade NVS now with 
Follow RTT